Navigation Links
Biomarker test for Peripartum Cardiomyopathy could help reduce death after giving birth
Date:5/17/2014

Athens, 17 May 2014: Cardiologists have discovered biomarkers that can be used to develop a screening test to detect Peripartum Cardiomyopathy (PPCM), a life-threatening disorder that is the primary cause of mortality in pregnant women in developing countries. The results, which can lead to the immediate treatment of PPCM in new mothers and a significant reduction in mortality, were presented at Heart Failure 2014, which opened the World Congress on Acute Heart Failure in Athens the 17 to the 20 May.

"For pregnant women there are two major causes of death: massive hemorrhage and PPCM, and it is a very sad situation because a time of great happiness turns to great sorrow and the new baby and the father are left alone," said study co-author Professor Alexandre Mebazaa, from the Hopital Lariboisiere, Paris. "Here we have found a way to detect rather quickly whether the woman has PPCM and to treat it quickly and efficiently."

PPCM is the leading cause of death in women who are pregnant or have just given birth in Haiti, South African and Egypt, according to the study's authors. Treatment was often delayed because it was difficult to know whether the women were experiencing normal symptoms of pregnancy or PPCM. The new discovery will allow doctors to administer a blood test to determine whether the woman has PPCM and begin effective treatment immediately.

"There's an urgent need for biomarkers of PPCM since the condition can be hard to differentiate from the normal symptoms of pregnancy that include dyspnoea, oedema and palpitations", said Professor Karen Sliwa, a co-author from the University of Cape Town, South Africa.

The authors hypothesized that since angiogenesis and relaxin-2 pathways are altered in PPCM the biomarkers ratio of these two pathways placental growth factors/sFlt-1 and relaxin-2 could be used to discriminate PPCM among peripartum women.

In the study, plasma was withdrawn from 77 PPCM patients, 75 healthy peripartum women, 25 breast feeding mothers, and 65 non-pregnant acute heart failure (HF) patients and tested for levels of cardiovascular (NT-proBNP), anti- (sFlt-1) and angiogenic [Placental (PlGF) or vascular endothelial (VEGF)] .

Results showed that compared to the other groups, PPCM patients had significantly higher levels of NT-proBNP, lower levels of plasma relaxin-2, and that the sFlt-1/PlGF ratio and sFlt-1/VEGF ratio were statistically lower.

"The next step will be to confirm our findings in a larger cohort and if they hold we could go on to develop a bed side test similar to NT-pro BNP in HF," said Professor Sliwa.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-622-834-576
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Researchers present findings on promising biomarker for esophageal cancer
2. Microfluidic technology reveals potential biomarker for early pancreatic cancer
3. NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials
4. Proteomics International biomarker study closer to a CDx test for diabetic kidney disease
5. Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
6. New study looks at biomarkers in assessing pitch counts bearing on injury
7. Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
8. Game changer: Biomarker identified for noncancerous pancreatic cysts
9. Lung and bladder cancers have common cell-cycle biomarkers
10. Brain biomarker shows promise in heart
11. Biomarkers in blood show potential as early detection method of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... VA (PRWEB) , ... January 18, 2017 , ... Floundering ... American Heart Month and the perfect time for a reset. The U.S. Apple Association ... studies to combat many of the factors that contribute to heart disease. , The ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... a point of difference. Eden Activewear is a stand-out company for several differences ... exclusively online and only manufacture on demand, this is called 'Agile' manufacturing - ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart ... Innovation of the Year. , Each year, Pink Elephant recognizes a new ... approach to address a specific business problem or opportunity. The award highlights original innovations ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Palm Desert, is opening a new office in San Clemente, California this month. ... (dTMS) in Southern California, successfully treating individuals struggling with major depression. Depression impacts ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... SightMD – will lecture to primary eye care practitioners on the latest breakthroughs ... the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017 In China , we ... the Upgrade of China,s Healthy Strategy ... Plan for Economic and Social Development of the ... and the state council of the People,s Republic ... emerging industry development plan, identifying medical devices as one of ...
(Date:1/18/2017)... Invetech, the leading developer of ... , has announced a collaboration agreement with Erytech ... treatments for acute leukemia and other oncology indications ... will develop systems to enable the commercial-scale manufacture ... platform, which uses a novel technology to encapsulate ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017  Tarix Orphan ... Administration has granted a Rare Pediatric Disease (RPD) designation ... of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic ... RDEB and treatment is limited to supportive care. ... the Orphan Drug Designation previously granted by the FDA ...
Breaking Medicine Technology: